- Home
- Products
- Customized FluoroAb™
- CD40
- Anti-CD40 MAb (Clone 10)-iFluor® 350 Succinimidyl Ester
Anti-CD40 MAb (Clone 10)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1180)
This product is comprised of an Human Anti-CD40 IgG1-kappa (Clone 10) labeled with iFluor® 350 Succinimidyl Ester. iFluor® 350 Succinimidyl Ester is a Blue-fluorescent dye and it's excitation/emission is 345/450 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- CD40
- Alternative Names
- CD40; CD40 molecule; TNF receptor superfamily member 5; TNFRSF5; tumor necrosis factor receptor superfamily; member 5; tumor necrosis factor receptor superfamily member 5; Bp50; p50; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily; member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CDW40; TNFRSF5; MGC9013;
- Overview
- This gene is a member of the TNF-receptor superfamily. The encoded protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions. Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. Mutations affecting this gene are the cause of autosomal recessive hyper-IgM immunodeficiency type 3 (HIGM3). Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
- Overview
- Human Anti-CD40 IgG1-kappa (Clone 10)
- Species Reactivity
- Human
- Name
- iFluor® 350 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 345/450
- Detection method
- Fluorescent
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Visilizumab-iFluor 568 (CAT#: ADC-FL-583)
- Anti-CD40 MAb (Clone 17)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4263)
- Anti-ERBB3 MAb (Clone 6)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS12020)
- Anti-SLC44A4 MAb (Clone 3)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14319)
- Anti-MS4A1 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14122)
- Anti-NGcGM3 MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9999)
- Eculizumab-Cy3 (CAT#: ADC-FL-248)
- Anti-MSTN MAb (Clone 8)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1427)
- Anti-MET MAb (Clone 4)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1397)
- Anti-FCER2 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14060)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS1180. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
CAT# | Product Name | Linker | Payload |
ADC-W-904 | Anti-CD40 (Teneliximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-905 | Anti-CD40 (Teneliximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-911 | Anti-CD40 (Lucatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-907 | Anti-CD40 (Teneliximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-903 | Anti-CD40 (Teneliximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.